CAN/OLE Sample Record
A N - 1819294
V N - 9712
R E - 97119294
T I - Treatment of chronic hepatitis D with interferon alfa-2a.
A U - Farci P; Mandas A; Coiana A; Lai M E; Desmet V; Van Eyken P; Gobi Y; Caruso L; Scaccabarozzi S; et al
C S - Hepatitis Viruses Section, Lab. Infectious Diseases, Natl. Inst. Allergy Infectious Diseases, Natl. Inst.
Health, Build. 7, Rm 200, 9000 Rockville Pike, Bethesda, MD 20892, USA
P U - New England Journal of Medicine1994, 330 (2); 88-94.
N U - ISSN 0028-4793
L A - English
C C - *10006 Clinical Biochemistry; General Methods and Applications
*10808 Enzymes-Physiological Studies
*12508 Pathology, General and Miscellaneous-Inflammation and Inflammatory Disease
*12512 Pathology, General and Miscellaneous-Therapy (1971- )
*13012 Metabolism-Proteins, Peptides and Amino Acids
*13014 Metabolism-Nucleic Acids, Purines and Pyrimidines
*14006 Digestive System-Pathology
*15008 Blood, Blood-Forming Organs and Body Fluids-Lymphatic Tissue and Reticuloendothelial
System
*17002 Endocrine System-General
*22005 Pharmacology-Clinical Pharmacology (1972- )
*22014 Pharmacology-Digestive System
*22016 Pharmacology-Endocrine System
*36006 Medical and Clinical Microbiology-Virology
*38506 Chemotherapy-Antiviral Agents
10062 Biochemical Studies-Nucleic Acids, Purines and Pyrimidines
10064 Biochemical Studies-Proteins, Peptides and Amino Acids
10068 Biochemical Studies-Carbohydrates
31500 Genetics of Bacteria and Viruses
B C - 02600 Animal Viruses-General (1993- )
86215 Hominidae
T X - Animals; Chordates; Humans; Mammals; Microorganisms; Primates; Vertebrates; Viruses
N O - Biological Abstracts Vol. 097 Iss. 006 Ref. 069169
D E - RESEARCH ARTICLE; HUMAN; INTERFERON-ALPHA-2A; ANTIVIRAL-DRUG; HORMONE-DRUG;
ALANINE AMINOTRANSFERASE; VIRAL RNA; POST-TREATMENT RELAPSE
A B - Background and Methods. Chronic hepatitis D is a severe and rapidly progressive liver disease for
which no therapy has been proved effective. To evaluate the efficacy of treatment with interferon, we
studied 42 patients with chronic hepatitis D who were randomly assigned to receive either 9 million
or 3 million units of recombinant interferon alfa-2a (three times a week for 48 weeks) or no
treatment. Results. By the end of the treatment period, serum alanine aminotransferase values had
become normal in 10 of 14 patients receiving 9 million units (71 percent), as compared with 4 of
14 treated with 3 million units (29 percent, P = 0.029) and 1 of 13 untreated controls (8 percent,
P = 0.001). Seven patients treated with the higher dose of interferon (50 percent) had a complete
response (normal levels of alanine aminotransferase and no detectable serum hepatitis delta virus
(HDV) RNA), as compared with three of those who received the lower dose (21 percent, P = 0.1 18),
and none of the controls (P = 0.004). Treatment with 9 million units of interferon was associated
with a marked improvement in the histologic findings (reduced periportal necrosis and portal and
lobular inflammation), whereas in the untreated controls there was considerable histologic
deterioration. In 5 of the 10 patients treated with 9 million units of interferon whose alanine
aminotransferase values became normal, the biochemical responses persisted for up to 4 years
(mean, 39 months), but the effects of treatment on viral replication were not sustained. In contrast,
q
q
q
S a m p l e R e c o r d s b y S e a r c h S y s t e m
2 5
S a m p l e R e c o r d s b y
S e a r c h S y s t e m
